Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 3c
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.17, $0.03 better than the analyst estimate of $0.14. Revenue for the quarter came in at $67.9 million versus the consensus estimate of $69.75 million.
GUIDANCE:
Vanda expects to achieve the following financial objectives in 2021:
Full Year 2021 Guidance | |
Total revenues | $270 to $300 million |
HETLIOZ® net product sales | $180 to $200 million |
Fanapt® net product sales | $90 to $100 million |
Year-end 2021 Cash | Greater than $400 million |
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.